Blau syndrome-associated uveitis and the NOD2 gene

Seminars in Ophthalmology

Volumn 28, Issue 5-6, 2013, Pages 327-332

  Pillai, Parvathy ^a   Sobrin, Lucia ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blau syndrome; NOD2; Pediatric uveitis

Indexed keywords

CANAKINUMAB; CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; PEPTIDOGLYCAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; BLAU SYNDROME; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; EYE INFLAMMATION; GENE; GENE EXPRESSION; GENE MAPPING; GENE MUTATION; GENETIC LINKAGE; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; MORBIDITY; NONHUMAN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN CONTAINING PROTEIN 2 GENE; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; UVEITIS;

CRANIAL NERVE DISEASES; HUMANS; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; SYNOVITIS; UVEITIS;

EID: 84886422277     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2013.825285     Document Type: Article

References (48)

1. Martin TM, Doyle TM, Smith Jr. Dinulesu D, et al. Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003;136: 933-935.
2. Kurko J, Besenyei T, Laki J, et al. Genetics of rheumatoid arthritis: A comprehensive review. Clin Rev Allergy Immunol. 2013;5.
3. Fischer A, Nothagel M, Schürmann M, et al. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered biallelic markers. Chest 2010; 138(1):151-157.
4. Blau EB. Familial granulomatous arthritis, iritis and rash. J Pediat. 1985;107:689-693.
5. Jabs DA, Houk JL, Bias WB, Arnett FC. Familial granu-lomatous synovitis, uveitis, and cranial neuropathies. Am J Med 1985;78:801-804.
6. Miller III JJ. Early-onset sarcoidosis and "familial granu-lomatous arthritis (arteritis)": The same disease. J Pediatr 1986;109(2):109387- 109388.
7. Saini SK and Rose CD. Liver involvement in familial granulomatous arthritis (Blau syndrome). J Rheum 1996;23: 396-399.
8. Ting SS, Ziegler J, Fischer E. Familial granulomatous arthritis (Blau syndrome) with granulomatous renal lesions. J Pediatr 1998;133:450-452.
9. Emaminia A, Nabavi M, Mousavi NM, Kashef S. Central nervous system involvement in Blau syndrome: A new feature of the syndrome? J Rheumatol 2007;34(12): 2504-2505.
10. Masel G, Halbert A. Blau syndrome presenting with ichthyosis. Australas J Dermatol 2005;46:29-32.
11. Wang X, Kuivaniemi H, Bonavita G, et al. CARD15 mutations in familial granulomatosis syndromes. Arthritis Rheum 2002;46(11):3041-3045.
12. Mourad F, Tang A. Sinus of vaslava aneurysm in Blau's syndrome. J Cardiothorac Surd 2010;5:16.
13. Raju P, Hasija R, Touitou I, et al. Blau arteritis resembling Takayasu Disease with a novel NOD2 Mutation. J Rheumatol 2012;39:1888-1892.
14. Rose CD, Arostegui JI, Martin TM, et al. NOD2-Associated pediatric granulomatous arthritis, an expanding pheno-type: Study of an international registry and a national cohort in Spain. Arthritis Rheum 2009;60:1797-1803.
15. Latkany PA, Jabs DA, Smith JR, et al. Multifocal choroiditis in patients with familial juvenile systemic granulomatosis. Am J Ophthalmol 2002;134:897-904.
16. Gass DA 2nd, Maender J, Metry D, et al. Two pediatric cases of Blau syndrome. Dermatology Online Journal 2009; 15:5.
17. Tromp G, Kuivaniemi H, Raphael S, et al. Genetic linkage of familial granulomatosis inflammatory arthritis, skin rash and uveitis to chromosome 16. Am J Hum Genet 1996; 59:1097-1107.
18. Okafuji I, Nishikomori R, Kanazawa N, et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum 2009;60: 242-250.
19. Pattishell EN, Strope GL, Spinola SM, Denny FW. Childhood sarcoidosis. Pediatrics 1986;108:169-177
20. Kanazawa N, Matsushima S, Kambe N, et al. Presence of a sporadic case of systemic granulomatosis syndrome with a CARD15 mutation. J Invest Derm 2004;122:851-852.
21. Rose CD, Doyle TM, McIlvain-Simpson G, et al. Blau syndrome mutation of CARD15/NOD2 in sporadic early onset granulomatous arthritis. J Rheumatol 2005;32:373-375.
22. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nature Genet 2001;29:19-20.
23. Raiji VR, Miller MM, Jung LK. Uveitis in Blau syndrome from a de novo mutation of the NOD2/CARD15 gene. J AAPOS 2011;15:205-207.
24. Saulsbury FT, Wouters CH, Martin TM, et al. Incomplete penetrance of the NOD2 E383K substitution among members of a pediatric granulomatous arthritis pedigree. Arthritis Rheum 2009;60:1804-1806.
25. Kanazawa N, Okafuji I, Kambe N, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-KB activation: Common genetic etiology with Blau syndrome. Blood 2005;10(3):1195-1197.
26. Snyers B, Dahan K. Blau syndrome associated with a CARD15/NOD2 mutation. Am J Ophthalmol 2006;142(6): 1421089-1421092.
27. Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-KB. J Biol Chem 2001;276(7):4812-4818.
28. Eckmann L, Karin M. NOD2 and Crohn's disease: Loss or gain of function? Immunity 2005;22(6):661-667
29. Sfriso P, Caso F, Tognon S, et al. Blau syndrome, clinical and genetic aspects. Autoimmunity Reviews 2012;12:44-51.
30. Rosenzweig HL, Martin TM, Jann MM, et al. NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci 2008;49: 1518-1524.
31. Rosenzweig HL, Kawaguchi T, Martin TM, et al. Nucleotide oligomerization domain-2(NOD2) induced uveitis: Dependence on IFN gamma. IOVS 2009 Apr: 1739-1745.
32. Rosenbaum JT, Planck SR, Davey MP, et al. With a mere nod, uveitis enters a new era. Am J Ophthalmol 2003;136: 729-732.
33. Davey MP, Martin TM, Planck SR, et al. Human endo-thelial cells express NOD2/CARD15 and increase IL-6 secretion in response to muramyl dipeptide. Microvascular Res 2006;71:103-107.
34. Rosenzweig HL, Martin TM, Planck SR, et al. Activation of NOD2 in vivo induces IL-1beta production in the eye via caspase-1 but results in ocular inflammation independently of IL-1 signaling. J Leukoc Biol 2008 Aug;84(2): 529-536.
35. Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol 2010;11:55-62.
36. Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 2010;16:90-97.
37. Zhu K, Yin X, Tang X, et al. Meta-analysis of NOD2/CARD15 polymorphisms with psoriasis and psoriatic arthritis. Rheumatol Int 2012;32(7):1893-1900.
38. Nguyen Y, Al-Lehibi A, Gorbe E, et al. Insufficient evidence for the association of NOD2/CARD15 or other inflammatory bowel disease associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. Blood 2010;115(17):3625-3631.
39. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
40. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Chrohn's disease. Nature 2001;411:603-606.
41. Inohara H, Chamaillard M, McDonald C, Nuñez G. NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 2005;74: 355-383.
42. Milman N, Andersen CB, Hansen A, et al. Favourable effect of TNF-alpha inhibitor (infliximab) on Blau syndrome in monozygotic twins with a de novo CARD15 mutation. APMIS 2006;14:912-919.
43. Rose CD, Martin TM, Wouters CH. Blau syndrome revisited. Curr Opin Rheumatol 2011;23:411-418.
44. Yasui K, Yashiro M, Tsuge M, et al. Thalidomide dramatically improves the symptoms of early-onset sarcoidosis/Blau syndrome: Its possible action and mechanism. Arthritis Rheum 2010;63:250-257.
45. Cunningham Jr ET. Uveitis in children. Ocul Immunol Inflamm 2000;8:251-261.
46. Aróstegui JI, Arnal C, Merino R, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum 2007 Nov;56(11): 3805-3813.
47. Martin TM, Zhang Z, Kurz P, et al. The NOD2 defect in Blau Syndrome does not result in excess interleukin-1 activity. Arthritis Rheum 2009;60(2):611-618.
48. Simonini G, Xu Z, Caputo R, et al. Clinical and transcrip-tional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum 2013;65(2):513-518.